|
Aug 31
|
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
|
|
Aug 30
|
Catalent delays filing of annual report
|
|
Aug 30
|
Eli Lilly ramps up its fight against imitation weight-loss drugs
|
|
Aug 30
|
The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
|
|
Aug 30
|
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
|
|
Aug 30
|
Wegovy reduces Covid-19 deaths and illness, study finds
|
|
Aug 30
|
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
|
|
Aug 29
|
Catalent beats revenue estimates ahead of deal close with Novo Holdings
|
|
Aug 29
|
Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day
|
|
Aug 28
|
Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound
|
|
Aug 28
|
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
|
|
Aug 28
|
Denmark’s Top Pension Fund Buys Weight-Loss Stocks After Run-Up
|
|
Aug 28
|
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
|
|
Aug 28
|
Five alternatives to Mag 7 stocks if you missed out on Nvidia
|
|
Aug 27
|
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
|
|
Aug 27
|
Eli Lilly Offers a Cheaper Form of Zepbound. Why Hims & Hers Stock Is Falling.
|
|
Aug 27
|
Zepbound and Other Weight-Loss Drugs Get More Good News. Why It’s Too Soon to Celebrate.
|
|
Jul 30
|
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
|
|
Jul 29
|
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Jul 29
|
Wall Street is still jittery on GLP-1s
|